Albireo Pharma Inc Revenue Growth Rates (ALBO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Albireo Pharma inc   (NASDAQ: ALBO)
 

ALBO's Revenue Growth by Quarter and Year

Albireo Pharma Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ALBO Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September 9.83
2nd Quarter June 8.21
1st Quarter March 6.83
FY 24.87

ALBOs Annual Revenue
Albireo Pharma Inc 's Revenue in the fiscal year 2021 $ 40.58 millions
Albireo Pharma Inc 's Revenue in the fiscal year 2020 $ 8.31 millions
Albireo Pharma Inc 's Revenue in the fiscal year 2019 $ 9.64 millions
Albireo Pharma Inc 's Revenue in the fiscal year 2018 $ 12.74 millions
Albireo Pharma Inc 's Revenue in the fiscal year 2017 $ 0.00 millions




ALBO Revenue third quarter 2022 Y/Y Growth Comment
Albireo Pharma inc reported Revenue surge of 168.63% year on year in the third quarter 2022, to $ 9.83 millions, this is lower than Albireo Pharma Inc 's recent average Revenue surge of 70371.86%.

Looking into third quarter 2022 results within Major Pharmaceutical Preparations industry 43 other companies have achieved higher Revenue growth. While Albireo Pharma Inc ' s Revenue doubling of 168.63% ranks overall at the positon no. 230 in the third quarter 2022.


ALBO Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December - 1095.59 % -57.7 % 1028.07 %
3rd Quarter September 168.63 % 71.83 % 53.24 % 479.17 %
2nd Quarter June 237.86 % 27.23 % 52.8 % 71.23 %
1st Quarter March 246.7 % 27.1 % 171.93 % -94.91 %
FY   - 388.33 % -13.8 % -

Financial Statements
Albireo Pharma Inc 's third quarter 2022 Revenue $ 9.83 millions ALBO's Income Statement
Albireo Pharma Inc 's third quarter 2021 Revenue $ 3.66 millions Quarterly ALBO's Income Statement


ALBO Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December - 788.52 % 27.7 % 362.59 %
3rd Quarter September 19.76 % 50.62 % 11.52 % 11.2 %
2nd Quarter June 20.2 % 23.35 % 23.23 % 119.3 %
1st Quarter March -79 % -27.57 % -75.89 % 0 %
FY (Year on Year)   - 388.33 % -13.8 % -


Back to ALBO Growth rate Comparisons >> Back to ALBO Growth rate Comparisons >>


Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #44
Healthcare Sector #68
Overall #230

Revenue Y/Y Growth Statistics
High Average Low
1120100 % 70371.86 % -94.91 %
(Mar 31 2018)   (Mar 31 2019)
Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #44
Healthcare Sector #68
Overall #230
Revenue Y/Y Growth Statistics
High Average Low
1120100 % 70371.86 % -94.91 %
(Mar 31 2018)   (Mar 31 2019)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Albireo Pharma Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
787.58 % 63.29 % -100 %
(Dec 31 2021)  


ALBO's III. Quarter Q/Q Revenue Comment
Albireo Pharma inc achieved in the III. Quarter 2022 below company average Revenue jump of 19.76% quarter on quarter, to $ 9.83 millions.

Within Major Pharmaceutical Preparations industry 35 other companies have achieved higher Revenue quarter on quarter growth. While Albireo Pharma Inc 's Revenue growth quarter on quarter, overall rank is 236.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #36
Healthcare Sector #55
Overall #236
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #36
Healthcare Sector #55
Overall #236
Revenue Q/Q Growth Statistics
High Average Low
787.58 % 63.29 % -100 %
(Dec 31 2021)  


ALBO's III. Quarter Q/Q Revenue Comment
Albireo Pharma inc achieved in the III. Quarter 2022 below company average Revenue jump of 19.76% quarter on quarter, to $ 9.83 millions.

Within Major Pharmaceutical Preparations industry 35 other companies have achieved higher Revenue quarter on quarter growth. While Albireo Pharma Inc 's Revenue growth quarter on quarter, overall rank is 236.


Albireo Pharma Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Sep 30 2021)
Cumulative Revenue 12 Months Ending $ 57.39 $ 51.22 $ 45.45 $ 40.58 $ 10.77
Y / Y Revenue Growth (TTM) 432.68 % 454.3 % 420.86 % 388.43 % -10.39 %
Year on Year Revenue Growth Overall Ranking # 3023 # 54 # 89 # 32 # 2851
Seqeuential Revenue Change (TTM) 12.04 % 12.71 % 11.99 % 276.64 % 16.59 %
Seq. Revenue Growth (TTM) Overall Ranking # 1537 # 573 # 521 # 22 # 2248


Cumulative Revenue growth Comment
Assuming the Albireo Pharma Inc 's fiscal year would have ended in Sep 30 2022, Albireo Pharma Inc would have reprted above average annual Revenue surge of 432.68% year on year, of $ 57 millions.
This marks a slow-down of the companys growth trends and from the 454.3% surge in Jun 30 2022.

In the Healthcare sector 436 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 54 to 3023.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 100
Healthcare Sector # 437
Overall # 3023

Revenue TTM Y/Y Growth Statistics
High Average Low
454.3 %
 187.32 %
-67.02 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 100
Sector # 230
S&P 500 # 1537
Cumulative Revenue growth Comment
Assuming the Albireo Pharma Inc 's fiscal year would have ended in Sep 30 2022, Albireo Pharma Inc would have reprted above average annual Revenue surge of 432.68% year on year, of $ 57 millions.
This marks a slow-down of the companys growth trends and from the 454.3% surge in Jun 30 2022.

In the Healthcare sector 436 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 54 to 3023.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 100
Healthcare Sector # 437
Overall # 3023

Revenue TTM Y/Y Growth Statistics
High Average Low
454.3 %
187.32 %
-67.02 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 100
Sector # 230
S&P 500 # 1537




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ALBO's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2022
Apellis Pharmaceuticals Inc 290.37%$ 290.372 millions
Babylon Holdings Limited287.98%$ 287.980 millions
Aurinia Pharmaceuticals Inc 280.30%$ 280.303 millions
Sera Prognostics Inc 278.26%$ 278.261 millions
Mirum Pharmaceuticals Inc 275.60%$ 275.600 millions
Evofem Biosciences Inc 272.14%$ 272.138 millions
Fresh Tracks Therapeutics Inc 268.18%$ 268.182 millions
Talis Biomedical Corporation265.14%$ 265.138 millions
Biorestorative Therapies Inc 262.50%$ 262.500 millions
Vir Biotechnology Inc 261.49%$ 261.486 millions
Igc Pharma Inc 260.71%$ 260.714 millions
Arvinas Inc 257.57%$ 257.574 millions
Arcus Biosciences Inc 254.94%$ 254.941 millions
Ideaya Biosciences Inc 230.87%$ 230.871 millions
Agape Atp Corporation229.81%$ 229.806 millions
Intra cellular Therapies Inc 223.63%$ 223.634 millions
Pear Therapeutics Inc 211.44%$ 211.442 millions
Revolution Medicines Inc 204.81%$ 204.814 millions
Harpoon Therapeutics Inc 203.68%$ 203.680 millions
Scynexis Inc 201.74%$ 201.744 millions
Tenon Medical Inc 197.14%$ 197.143 millions
Vbi Vaccines Inc196.26%$ 196.262 millions
Sutro Biopharma Inc 195.26%$ 195.257 millions
Statera Biopharma Inc fka Cytocom Inc 183.48%$ 183.475 millions
Bolt Biotherapeutics Inc 180.85%$ 180.851 millions
Rennova Health Inc 179.73%$ 179.728 millions
Hoth Therapeutics Inc 177.78%$ 177.775 millions
Geron Corporation172.48%$ 172.477 millions
Xeris Biopharma Holdings Inc 168.76%$ 168.761 millions
Albireo Pharma inc 168.34%$ 168.341 millions


About Albireo Pharma Inc Revenue Growth Rates (ALBO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Albireo Pharma Inc (CIK 1322505).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001558370-22-016893
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Albireo Pharma Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.